Announcements Trials
Browse Landscape

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 16Carcinoma, Hepatocellular 11Stomach Neoplasms 6Neoplasms 5Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Myositis 2Lung Neoplasms 2Cholangiocarcinoma 2Vascular Complications 1Sjogren's Syndrome 1Scleroderma, Systemic 1Sarcopenia 1Recurrence 1Rectal Neoplasms 1Plaque, Atherosclerotic 1Pathologic Complete Response 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Metastatic Colorectal Adenocarcinoma 1Melanoma 1Lupus Erythematosus, Systemic 1Lung Diseases, Interstitial 1Liver Neoplasms 1Influenza, Human 1Immune-Related Adverse Events 1

Interventions

lenvatinib 3Surgical Procedures, Operative 3Hepatectomy 3Cholangiopancreatography, Endoscopic Retrograde 3Blood Specimen Collection 3Oxaliplatin 2Liquid Biopsy 2Immunohistochemistry 2Immune Checkpoint Inhibitors 2Drug Therapy 2Base Sequence 2pembrolizumab 1gemcitabine-oxaliplatin regimen 1envafolimab 1Vascular Endothelial Growth Factor A 1Urination 1Tegafur 1Shadowing Technique, Histology 1S 1 (combination) 1Radiotherapy 1Quality of Life 1Polymerase Chain Reaction 1Photochemotherapy 1Patient Reported Outcome Measures 1Pancreaticoduodenectomy 1Palliative Care 1Observation 1Neoadjuvant Therapy 1Molecular Diagnostic Techniques 1Microbiota 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Cholangiocarcinoma × Immune Checkpoint Inhibitors × Clear all
NCT06505486 2024-07-17

GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting
21 enrolled
Gastrointestinal

Cholangiocarcinoma

NCT05489692 2022-08-10

HAIC Plus Targeted Therapy and/or PD-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma

Sun Yat-sen University

Completed
43 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡